Chloroquine 250mg Tablet Franchise in Ahmedabad

Anti-Malarial Medicine Supplier in Bangalore

Chloroquine Tablet Distributor in Hyderabad

Malaria Treatment Tablet Franchise Opportunity in Jaipur

Preventive Malaria Medicine Stockist in Mumbai
Chloroquine Tablet Export & Manufacturing in Chandigarh

Home/Products /chloroquine-250mg-tablet

Quinhub 250 Tablet

Composition : Chloroquine (250mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹1/-

Quinhub 250 Tablet contains Chloroquine 250mg, a widely used anti-malarial medicine effective against Plasmodium species causing malaria. It works by inhibiting parasite growth in red blood cells, helping prevent and treat acute malaria attacks as well as providing prophylactic protection.

The formulation ensures fast absorption and predictable therapeutic action, making it suitable for hospital use, outpatient care, and travel prophylaxis. Chloroquine is highly recommended in endemic regions and for patients at risk of malaria infection.

For distributors and resellers, Quinhub 250 Tablet is a high-demand anti-malarial product, consistently prescribed in hospitals, tropical disease centers, clinics, and government malaria programs. Its critical role in malaria management ensures steady movement and recurring institutional demand throughout the year.

Adding Quinhub 250 Tablet to your portfolio strengthens your anti-malarial and hospital-care segment, offering opportunities for bulk hospital supply, government tenders, private hospital chains, export markets, and third-party manufacturing. Its essential use in malaria prevention and treatment makes it a profitable and strategically important product for pharmaceutical distributors.

Read More

About the Product

Quinhub 250 Tablet contains Chloroquine 250mg, a widely used anti-malarial medicine effective against Plasmodium species causing malaria. It works by inhibiting parasite growth in red blood cells, helping prevent and treat acute malaria attacks as well as providing prophylactic protection.

The formulation ensures fast absorption and predictable therapeutic action, making it suitable for hospital use, outpatient care, and travel prophylaxis. Chloroquine is highly recommended in endemic regions and for patients at risk of malaria infection.

For distributors and resellers, Quinhub 250 Tablet is a high-demand anti-malarial product, consistently prescribed in hospitals, tropical disease centers, clinics, and government malaria programs. Its critical role in malaria management ensures steady movement and recurring institutional demand throughout the year.

Adding Quinhub 250 Tablet to your portfolio strengthens your anti-malarial and hospital-care segment, offering opportunities for bulk hospital supply, government tenders, private hospital chains, export markets, and third-party manufacturing. Its essential use in malaria prevention and treatment makes it a profitable and strategically important product for pharmaceutical distributors.

Some patients may experience nausea, vomiting, headache, dizziness, or mild stomach discomfort. Rarely, visual disturbances, allergic reactions, or cardiac rhythm changes may occur.

It is indicated for the treatment and prophylaxis of malaria, including infections caused by Plasmodium falciparum and Plasmodium vivax. It helps reduce fever, chills, and other malaria-related symptoms.

Use only under medical supervision. Avoid in patients with known hypersensitivity to chloroquine or pre-existing retinal/eye disorders. Take as prescribed to prevent resistance.

Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation